Valuation: Agenus Inc.

Market Cap 35Cr 30Cr 28Cr 25Cr 48Cr 3.31TCr 48Cr 327.59Cr 127.38Cr 1.66TCr 129.65Cr 126.84Cr 5.49TCr P/E 2026 *
11.3x
P/E 2027 * -31.3x
Enterprise Value 35Cr 30Cr 28Cr 25Cr 48Cr 3.31TCr 48Cr 327.59Cr 127.38Cr 1.66TCr 129.65Cr 126.84Cr 5.49TCr EV / Sales 2026 *
2.46x
EV / Sales 2027 * 2.51x
Free-Float
93.77%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day-5.19%
1 week+7.27%
Current month+2.27%
1 month+28.26%
3 months+146.62%
6 months+138.20%
Current year+144.27%
1 week 7.31
Extreme 7.31
8.73
1 month 5.87
Extreme 5.87
8.85
Current year 2.71
Extreme 2.71
8.85
1 year 2.71
Extreme 2.71
8.85
3 years 1.38
Extreme 1.38
28.9
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 73 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap.
10/08/26 Free

Chief Executive Officer

19,71,500 4.4054%
05/08/26 Free

Director

50,000 0.1117%
05/08/26 Free

Director

50,000 0.1117%
Change 5-day change 1-year change 3-year change Capi.($)
-5.19%+7.27%+69.69%-71.17% 35Cr
-0.74%+3.78%+3.74%+23.10% 5.12TCr
+1.01%-0.20%+471.68%+564.93% 4.53TCr
+0.16%+7.88%+36.14%+20.76% 4.28TCr
-0.66%+2.61%+18.59%+87.04% 4.23TCr
+0.88%-3.48%+17.20%+53.83% 3.22TCr
-0.12%+3.84%+33.73%+145.25% 1.73TCr
-0.53%+1.84% - - 1.65TCr
+0.58%+4.66%+7.17%+30.87% 1.48TCr
+1.15%+4.17%+84.49%+50.33% 1.43TCr
Average -0.35%+3.96%+82.49%+100.55% 2.77TCr
Weighted average by Cap. +0.10%+3.08%+101.26%+141.10%

Financials

2026 *2027 *
Net sales 14Cr 12Cr 11Cr 10Cr 19Cr 1.34TCr 20Cr 133.1Cr 52Cr 674.58Cr 53Cr 52Cr 2.23TCr 14Cr 12Cr 11Cr 10Cr 19Cr 1.32TCr 19Cr 130.3Cr 51Cr 660.39Cr 52Cr 50Cr 2.19TCr
Net income 3.52Cr 3.02Cr 2.82Cr 2.58Cr 4.87Cr 337.05Cr 4.92Cr 33Cr 13Cr 169.25Cr 13Cr 13Cr 559.97Cr -2.61Cr -2.24Cr -2.09Cr -1.91Cr -3.61Cr -249.91Cr -3.65Cr -25Cr -9.63Cr -125.49Cr -9.8Cr -9.59Cr -415.21Cr
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Employees
81
Date Price Change Volume
24/26/24 $7.670 -5.19% 7,75,158
21/26/21 $8.090 +8.01% 15,17,511
20/26/20 $7.490 -9.32% 15,75,849
19/26/19 $8.260 +9.69% 22,90,360
18/26/18 $7.530 +5.31% 9,67,558
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.670USD
Average target price
19.50USD
Spread / Average Target
+154.24%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock